Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF35700 in Treatment-Resistant Schizophrenia
NCT03230864Phase 3Terminated
- Sponsor
- Lundbeck
- Start
- Jul 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of lu af35700 in schizophrenia, sponsored by Lundbeck. Started Jul 2017; status: terminated.
02
Drugs
lu af35700
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03230864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03230864.